Thus, we first developed a viable knockout mouse of mitochondrial TSPO and showed that TSPO deletion is protective in a mouse model of MS, indicating that mitochondrial TSPO is a novel therapeutic target for MS. Here, TSPO is linked to myeloid sarcoma.